EdiTy Therapeutics
2 known investors
Edity develops an AI-powered platform that engineers therapeutic proteins and uses immune cells (such as T-cells and NK cells) as carriers to deliver them to diseased tissues. Its plug-and-play technology is compatible with allogeneic approaches and aimed at creating new modalities for intracellular therapy.
AI & Machine LearningBiotechHealthtech
Investors · 2
Founder mafia
2 people who came through EdiTy Therapeutics went on to found or lead other companies.
Frequently asked questions
- What does EdiTy Therapeutics do?
- Edity develops an AI-powered platform that engineers therapeutic proteins and uses immune cells (such as T-cells and NK cells) as carriers to deliver them to diseased tissues. Its plug-and-play technology is compatible with allogeneic approaches and aimed at creating new modalities for intracellular therapy.
- Who are EdiTy Therapeutics's investors?
- EdiTy Therapeutics's investors include NFX, Tal Ventures.